{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T05:26:53Z","timestamp":1792992413092,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"23","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,6,30]]},"DOI":"10.1038\/s41388-025-03350-y","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T11:22:52Z","timestamp":1743074572000},"page":"1844-1855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["SUMOylation facilitates the stability of BCR-ABL to promote chronic myeloid leukemia progression"],"prefix":"10.1038","volume":"44","author":[{"given":"Lu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minran","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5919-7624","authenticated-orcid":false,"given":"Chunyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7316-8467","authenticated-orcid":false,"given":"Huan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1435-6716","authenticated-orcid":false,"given":"Sai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"3350_CR1","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343\u201356.","journal-title":"Blood"},{"key":"3350_CR2","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","volume":"398","author":"J Cortes","year":"2021","unstructured":"Cortes J, Pavlovsky C, Sau\u00dfele S. Chronic myeloid leukaemia. Lancet. 2021;398:1914\u201326.","journal-title":"Lancet"},{"key":"3350_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172\u201383.","journal-title":"Nat Rev Cancer."},{"key":"3350_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrm1280","volume":"5","author":"O Hantschel","year":"2004","unstructured":"Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol. 2004;5:33\u201344.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"3350_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med."},{"key":"3350_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3324\/haematol.2015.139337","volume":"101","author":"TI Mughal","year":"2016","unstructured":"Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, et al. Chronic myeloid leukemia: reminiscences and dreams. Haematologica. 2016;101:541\u201358.","journal-title":"Haematologica"},{"key":"3350_CR7","doi-asserted-by":"publisher","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","volume":"6","author":"L Ma","year":"2014","unstructured":"Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, et al. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med. 2014;6:252ra121.","journal-title":"Sci Transl Med"},{"key":"3350_CR8","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1038\/s41388-020-1253-0","volume":"39","author":"N Shibata","year":"2020","unstructured":"Shibata N, Ohoka N, Tsuji G, Demizu Y, Miyawaza K, Ui-Tei K, et al. Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells. Oncogene. 2020;39:3867\u201378.","journal-title":"Oncogene"},{"key":"3350_CR9","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1158\/0008-5472.CAN-17-1733","volume":"78","author":"C Liu","year":"2018","unstructured":"Liu C, Nie D, Li J, Du X, Lu Y, Li Y, et al. Antitumor effects of blocking protein Neddylation in T315I-BCR-ABL leukemia cells and leukemia stem cells. Cancer Res. 2018;78:1522\u201336.","journal-title":"Cancer Res"},{"key":"3350_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41580-022-00500-y","volume":"23","author":"ACO Vertegaal","year":"2022","unstructured":"Vertegaal ACO. Signalling mechanisms and cellular functions of SUMO. Nat Rev Mol Cell Biol. 2022;23:715\u201331.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"3350_CR11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrm3011","volume":"11","author":"JR Gareau","year":"2010","unstructured":"Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol. 2010;11:861\u201371.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3350_CR12","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1152\/physrev.00025.2019","volume":"100","author":"HM Chang","year":"2020","unstructured":"Chang HM, Yeh ETH. SUMO: from bench to bedside. Physiol Rev. 2020;100:1599\u2013619.","journal-title":"Physiol Rev."},{"key":"3350_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrm3478","volume":"13","author":"CM Hickey","year":"2012","unstructured":"Hickey CM, Wilson NR, Hochstrasser M. Function and regulation of SUMO proteases. Nat Rev Mol Cell Biol. 2012;13:755\u201366.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3350_CR14","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1182\/blood-2014-06-584524","volume":"124","author":"A Hoellein","year":"2014","unstructured":"Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, et al. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood. 2014;124:2081\u201390.","journal-title":"Blood"},{"key":"3350_CR15","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ccr.2014.04.008","volume":"25","author":"MV Bogachek","year":"2014","unstructured":"Bogachek MV, Chen Y, Kulak MV, Woodfield GW, Cyr AR, Park JM, et al. SUMOylation pathway is required to maintain the basal breast cancer subtype. Cancer Cell. 2014;25:748\u201361.","journal-title":"Cancer Cell"},{"key":"3350_CR16","first-page":"98","volume":"109","author":"L Gabellier","year":"2024","unstructured":"Gabellier L, De Toledo M, Chakraborty M, Akl D, Hallal R, Aqrouq M, et al. SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacytidine in preclinical models of acute myeloid leukemia. Haematologica. 2024;109:98\u2013114.","journal-title":"Haematologica"},{"key":"3350_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1182\/bloodadvances.2022007875","volume":"7","author":"GJJE Heynen","year":"2023","unstructured":"Heynen GJJE, Baumgartner F, Heider M, Patra U, Holz M, Braune J, et al. SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma. Blood Adv. 2023;7:469\u201381.","journal-title":"Blood Adv"},{"key":"3350_CR18","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1182\/blood.2021014267","volume":"139","author":"A Nakamura","year":"2022","unstructured":"Nakamura A, Grossman S, Song K, Xega K, Zhang Y, Cvet D, et al. The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation. Blood. 2022;139:2770\u201381.","journal-title":"Blood"},{"key":"3350_CR19","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1136\/gutjnl-2021-324834","volume":"71","author":"S Kumar","year":"2022","unstructured":"Kumar S, Schoonderwoerd MJA, Kroonen JS, de Graaf IJ, Sluijter M, Ruano D, et al. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model. Gut. 2022;71:2266\u201383.","journal-title":"Gut"},{"key":"3350_CR20","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nri2413","volume":"8","author":"K Ozato","year":"2008","unstructured":"Ozato K, Shin DM, Chang TH, Morse HC 3rd. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. 2008;8:849\u201360.","journal-title":"Nat Rev Immunol"},{"key":"3350_CR21","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.molcel.2007.11.012","volume":"28","author":"AV Ivanov","year":"2007","unstructured":"Ivanov AV, Peng H, Yurchenko V, Yap KL, Negorev DG, Schultz DC, et al. PhD domain-mediated E3 ligase activity directs intramolecular SUMOylation of an adjacent bromodomain required for gene silencing. Mol Cell. 2007;28:823\u201337.","journal-title":"Mol Cell."},{"key":"3350_CR22","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/nsmb.2077","volume":"18","author":"AA Goodarzi","year":"2011","unstructured":"Goodarzi AA, Kurka T, Jeggo PA. KAP-1 phosphorylation regulates CHD3 nucleosome remodeling during the DNA double-strand break response. Nat Struct Mol Biol. 2011;18:831\u20139.","journal-title":"Nat Struct Mol Biol."},{"key":"3350_CR23","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/ncb1446","volume":"8","author":"Y Ziv","year":"2006","unstructured":"Ziv Y, Bielopolski D, Galanty Y, Lukas C, Taya Y, Schultz DC, et al. Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway. Nat Cell Biol. 2006;8:870\u20136.","journal-title":"Nat Cell Biol"},{"key":"3350_CR24","doi-asserted-by":"publisher","first-page":"E1724","DOI":"10.1073\/pnas.1415569112","volume":"112","author":"B Yu","year":"2015","unstructured":"Yu B, Swatkoski S, Holly A, Lee LC, Giroux V, Lee CS, et al. Oncogenesis driven by the Ras\/Raf pathway requires the SUMO E2 ligase Ubc9. Proc Natl Acad Sci USA. 2015;112:E1724\u2013E1733.","journal-title":"Proc Natl Acad Sci USA."},{"key":"3350_CR25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41392-023-01450-3","volume":"8","author":"X Ma","year":"2023","unstructured":"Ma X, Jia S, Wang G, Liang M, Guo T, Du H, et al. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance. Signal Transduct Target Ther. 2023;8:246.","journal-title":"Signal Transduct Target Ther."},{"key":"3350_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44502-6","volume":"15","author":"J Ren","year":"2024","unstructured":"Ren J, Wang S, Zong Z, Pan T, Liu S, Mao W, et al. TRIM28-mediated nucleocapsid protein SUMOylation enhances SARS-CoV-2 virulence. Nat Commun. 2024;15:244.","journal-title":"Nat Commun."},{"key":"3350_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25033-4","volume":"12","author":"Y Qin","year":"2021","unstructured":"Qin Y, Li Q, Liang W, Yan R, Tong L, Jia M, et al. TRIM28 SUMOylates and stabilizes NLRP3 to facilitate inflammasome activation. Nat Commun. 2021;12:4794.","journal-title":"Nat Commun."},{"key":"3350_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-020-00432-z","volume":"6","author":"RY Zhang","year":"2021","unstructured":"Zhang RY, Liu ZK, Wei D, Yong YL, Lin P, Li H, et al. UBE2S interacting with TRIM28 in the nucleus accelerates cell cycle by ubiquitination of p27 to promote hepatocellular carcinoma development. Signal Transduct Target Ther. 2021;6:64.","journal-title":"Signal Transduct Target Ther"},{"key":"3350_CR29","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1038\/s41418-020-00701-y","volume":"28","author":"JO Jin","year":"2021","unstructured":"Jin JO, Lee GD, Nam SH, Lee TH, Kang DH, Yun JK, et al. Sequential ubiquitination of p53 by TRIM28, RLIM, and MDM2 in lung tumorigenesis. Cell Death Differ. 2021;28:1790\u2013803.","journal-title":"Cell Death Differ"},{"key":"3350_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07475-5","volume":"9","author":"KW Fong","year":"2018","unstructured":"Fong KW, Zhao JC, Song B, Zheng B, Yu J. TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression. Nat Commun. 2018;9:5007.","journal-title":"Nat Commun."},{"key":"3350_CR31","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/s41375-024-02276-w","volume":"38","author":"M Morii","year":"2024","unstructured":"Morii M, Kubota S, Iimori M, Yokomizo-Nakano T, Hamashima A, Bai J, et al. TIF1\u03b2 activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia. Leukemia. 2024;38:1275\u201386.","journal-title":"Leukemia"},{"key":"3350_CR32","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","volume":"147","author":"N Mizushima","year":"2011","unstructured":"Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147:728\u201341.","journal-title":"Cell"},{"key":"3350_CR33","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/ncb0910-836","volume":"12","author":"C Kraft","year":"2010","unstructured":"Kraft C, Peter M, Hofmann K. Selective autophagy: ubiquitin-mediated recognition and beyond. Nat Cell Biol. 2010;12:836\u201341.","journal-title":"Nat Cell Biol"},{"key":"3350_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14343-8","volume":"11","author":"AJ Jakobi","year":"2020","unstructured":"Jakobi AJ, Huber ST, Mortensen SA, Schultz SW, Palara A, Kuhm T, et al. Structural basis of p62\/SQSTM1 helical filaments and their role in cellular cargo uptake. Nat Commun. 2020;11:440.","journal-title":"Nat Commun."},{"key":"3350_CR35","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1182\/blood-2012-01-402578","volume":"120","author":"DJ Goussetis","year":"2012","unstructured":"Goussetis DJ, Gounaris E, Wu EJ, Vakana E, Sharma B, Bogyo M, et al. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood. 2012;120:3555\u201362.","journal-title":"Blood"},{"key":"3350_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32957-y","volume":"13","author":"S Jin","year":"2022","unstructured":"Jin S, He X, Ma L, Zhuang Z, Wang Y, Lin M, et al. Suppression of ACE2 SUMOylation protects against SARS-CoV-2 infection through TOLLIP-mediated selective autophagy. Nat Commun. 2022;13:5204.","journal-title":"Nat Commun."},{"key":"3350_CR37","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nsmb.1416","volume":"15","author":"L Zeng","year":"2008","unstructured":"Zeng L, Yap KL, Ivanov AV, Wang X, Mujtaba S, Plotnikova O, et al. Structural insights into human KAP1 PhD finger-bromodomain and its role in gene silencing. Nat Struct Mol Biol. 2008;15:626\u201333.","journal-title":"Nat Struct Mol Biol."},{"key":"3350_CR38","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med."},{"key":"3350_CR39","doi-asserted-by":"publisher","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","volume":"79","author":"GM Burslem","year":"2019","unstructured":"Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, et al. Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation. Cancer Res. 2019;79:4744\u201353.","journal-title":"Cancer Res"},{"key":"3350_CR40","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/anie.201507634","volume":"55","author":"AC Lai","year":"2016","unstructured":"Lai AC, Toure M, Hellerschmied D, Salami J, Jaime-Figueroa S, Ko E, et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016;55:807\u201310.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3350_CR41","doi-asserted-by":"publisher","first-page":"21683","DOI":"10.1073\/pnas.1016311108","volume":"107","author":"JH Mao","year":"2010","unstructured":"Mao JH, Sun XY, Liu JX, Zhang QY, Liu P, Huang QH, et al. As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc Natl Acad Sci USA. 2010;107:21683\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3350_CR42","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.molcel.2023.05.010","volume":"83","author":"F Yu","year":"2023","unstructured":"Yu F, Zhu AC, Liu S, Gao B, Wang Y, Khudaverdyan N, et al. RBM33 is a unique m6A RNA-binding protein that regulates ALKBH5 demethylase activity and substrate selectivity. Mol Cell 2023;83:2003\u2013.e6.","journal-title":"Mol Cell"},{"key":"3350_CR43","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/s41388-023-02689-4","volume":"42","author":"W Li","year":"2023","unstructured":"Li W, Han Q, Zhu Y, Zhou Y, Zhang J, Wu W, et al. SUMOylation of RNF146 results in Axin degradation and activation of Wnt\/\u03b2-catenin signaling to promote the progression of hepatocellular carcinoma. Oncogene. 2023;42:1728\u201340.","journal-title":"Oncogene"},{"key":"3350_CR44","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41580-018-0003-4","volume":"19","author":"I Dikic","year":"2018","unstructured":"Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19:349\u201364.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3350_CR45","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/onc.2010.561","volume":"30","author":"BJ Altman","year":"2011","unstructured":"Altman BJ, Jacobs SR, Mason EF, Michalek RD, MacIntyre AN, Coloff JL, et al. Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis. Oncogene. 2011;30:1855\u201367.","journal-title":"Oncogene"},{"key":"3350_CR46","doi-asserted-by":"publisher","first-page":"e157644","DOI":"10.1172\/JCI157644","volume":"132","author":"Y Luo","year":"2022","unstructured":"Luo Y, Li Z, Kong Y, He W, Zheng H, An M, et al. KRAS mutant-driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer. J Clin Invest. 2022;132:e157644.","journal-title":"J Clin Invest."},{"key":"3350_CR47","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1161\/CIRCRESAHA.122.321200","volume":"133","author":"X Zhou","year":"2023","unstructured":"Zhou X, Jiang Y, Wang Y, Fan L, Zhu Y, Chen Y, et al. Endothelial FIS1 desumoylation protects against hypoxic pulmonary hypertension. Circ Res. 2023;133:508\u201331.","journal-title":"Circ Res"},{"key":"3350_CR48","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nature21683","volume":"543","author":"M Imbeault","year":"2017","unstructured":"Imbeault M, Helleboid PY, Trono D. KRAB zinc-finger proteins contribute to the evolution of gene regulatory networks. Nature. 2017;543:550\u20134.","journal-title":"Nature"},{"key":"3350_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01399-3","volume":"20","author":"HH Park","year":"2021","unstructured":"Park HH, Kim HR, Park SY, Hwang SM, Hong SM, Park S, et al. RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment. Mol Cancer. 2021;20:107.","journal-title":"Mol Cancer."}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03350-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03350-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03350-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T19:03:18Z","timestamp":1749236598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03350-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":49,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,6,30]]}},"alternative-id":["3350"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03350-y","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors confirm that all methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from patients. Approval has been obtained from the Ethics Committee of Qilu Hospital of Shandong University (Grant No. KVLL-2023(ZM)-174).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}